

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.weylo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/555,894	11/07/2005	Jordi Tormo i Blasco	5000-0135PUS1	2720		
2292 BIRCH STEW	7590 04/02/200 ART KOLASCH & BI	EXAM	EXAMINER			
PO BOX 747			JARRELL, NOBLE E			
FALLS CHUI	RCH, VA 22040-0747	ART UNIT	PAPER NUMBER			
		1624				
			NOTIFICATION DATE	DELIVERY MODE		
			04/02/2008	ELECTRONIC		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail $\,$ address(es):

mailroom@bskb.com

Application No. Applicant(s) 10/555.894 TORMO I BLASCO ET AL Office Action Summary Examiner Art Unit Noble Jarrell 1624 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 16 January 2008. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1.2 and 5-16 is/are pending in the application. 4a) Of the above claim(s) 6-10 and 12 is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) 1-2,5,11,13-16 is/are rejected. 7) Claim(s) _____ is/are objected to. 8) Claim(s) _____ are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abevance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s)

1) Notice of References Cited (PTO-892)

Notice of Draftsperson's Patent Drawing Review (PTO-948)

Information Disclosure Statement(s) (PTO/S5/08)
 Paper No(s)/Mail Date ______.

Interview Summary (PTO-413)
 Paper No(s)/Mail Date.

6) Other:

5) Notice of Informal Patent Application

Application/Control Number: 10/555,894 Page 2

Art Unit: 1624

DETAILED ACTION

Current Status of 10 / 555894

 Claim objections have been overcome by the amendment filed 1/16/08. Since variable R⁴ can only be pyrazole or a triazole ring, claim 1 only contains elected subject matter.

Claims 1-2 and 5-16 are pending in the instant application. Since claims 6-10 and 12
are withdrawn, they are not being considered. Consequently, claims 1-2, 5, 11, and 13-16 are
being examined in this office action.

Rejections Maintained / New Rejections based on New or Amended Claims

Claim Rejections - 35 USC § 103

- The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:
 - Determining the scope and contents of the prior art.
 - 2. Ascertaining the differences between the prior art and the claims at issue.
 - Resolving the level of ordinary skill in the pertinent art.
 - Considering objective evidence present in the application indicating obviousness or nonobviousness.
- 5. Claims 1-2, 5, and 11, and 13-16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Grote et al. (WO 02/74753, published 26 September 2002, Reference BB of April 26, 2007 IDS). Grote et al. teach structures I-1 and I-29 in table 1 (page 36). The core structure for table I is shown below.

Art Unit: 1624

$$R^1$$
 R^2
 R^4
 R^5
 R^7
 R^9
 R^2
 R^6
 R^8

Core Structure for Table 1

The following table shows the groups for compounds I-1 and I-29.

Compound	R ¹	R ²	R ³	R⁴	R⁵	R ⁶	R ⁷	R ⁸	R ⁹
I-1	Pyrazolyl-1	CI	Isopropyl	Н	CI	F	Н	Н	Н
I-29	1,2,4-triazolyl	CI	Isopropyl	Н	C	F	Н	Ι	Н

These compounds render compounds of claim 1-2 and 5 obvious, except for the fact that they do not have an oxo group attached at the 5-position of the pyrazole and the triazole. Grote et al. do not explicitly prepare a compound of formula I where an oxo group is attached to the 5-position of the pyrazole or 1,2,4-triazole ring. However, on page 3, it states that variable R*, which is a substituent on the pyrazole or triazole ring, can be oxo, among other groups. The elected species, example 3, is held unobvious over compound I-2 of table 1, which only differs from compound I-1 in that R³ is (S)-CH(CH₃)CF₃ and R⁵ and R³ are F. Claim 11 is obvious over Grote et al. because on page 46, example 1, the reference discloses a composition consisting of 10 % of the active compound, 63 % cyclohexanone, and 27% of an emulsifier, for the purposes of treating leaves of an *Altemaria solani*. Based in this logic, Grote et al. are obvious over instant claims 1-2, 5, and 11.

Art Unit: 1624

The motivation for attaching variable R^a in Grote et al. (page 1, lines 25-34, of the specification) to variable R¹ in Grote et al. (page 1, lines 17-22, of the specification) is based on MPEP 2144.08, which cites *In Stratoflex, Inc. v. Aeroquip Corp.*, 713 F. 2d 1530. In this case, the court noted, "the question under 35 U.S.C. 103 is not whether the differences [between the claimed invention and the prior art] would have been obvious" but "whether the claimed invention as a whole would have been obvious." One of ordinary skill in the art would be motivated to make any of the species that are taught in the genus of the reference with a reasonable expectation of success of obtaining compounds with analogous properties. Thus, claims 1-2, 5, 11 and the elected species are unobvious over Grote et al. Claims 13-16 are rendered obvious because the ring can be substituted by an oxo, halogen, or Cr-C₆-alkyl, among other groups for variable R^a. In other words, Grote et al. are making hydrogen, an oxo, halogen, and C₁-C₆-alkyl groups equivalent to one another. This rejection is maintained because Grote et al. assert that an oxo group is equivalent to hydrogen because the ring can be substituted with any of the groups that are included as a part of variable R^a.

Double Patenting

- 6. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Omum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
- A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Art Unit: 1624

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

7. Claims 1-2, 5, 11, and 13-16 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-4 and 7 of U.S. Patent No. 7,153,860 ('860) (cited in previous office action). Although the conflicting claims are not identical, they are not patentably distinct from each other because they contain overlapping subject material as well as species that could be embraced by both sets of claims. Instant claims 1-3 and 5 overlap with claims 1-4 of '860. The following table shows example of overlap between the instant claims and the claims of '860.

Instant claims 1-2, 5	<u>'860 claims 1-4</u>				
\mathbb{R}^d is $Y = \mathbb{C} \text{ or } \mathbb{N}$	R ¹ is pyrazole, 1,2,4-triazole, 1,23-triazole, etc.				
R ^a is hydrogen, alkyl,	R ^a is halogen, hydroxyl, cyano, oxo, nitro				
cycloalkyl	amino, mercapto, etc.				
R ¹ , R ² are C ₁ -C ₆ -alkyl	R₃, R₄ are hydrogen, alkyl				
L _n where L is halogen,	R ⁵ : halogen, R ⁶ : hydrogen, halogen, alkyl;				
cyano, alkyl and n is 1-5	R ⁷ , R ⁸ , R ⁹ : hydrogen, halogen, alkyl				

Variable R⁴ of the instant claims is equivalent to the combined groups R¹ and Rⁿ of '860 because Rⁿ is a substituent of ring R¹ in the '860 claims. It is important to note an oxo group is

Art Unit: 1624

one possibility for variable Ra in '860, and therefore a case for obvious-type double patenting is made between the instant claims and '860. In addition, there are 2 more sets of equivalencies; R^1 and R^2 of the instant claims are equivalent to R_3 and R_4 of '860, and L_6 of the instant claims is equivalent to variables R⁵ through R⁹ of '860. Two examples of species that can be embraced by both sets of claims are species of tables 1 and 11 of '860 (column 12, lines 24-40 and column 13, lines 25-40). When variables R3 and R4 are both ethyl (as in entry A-3 of table A (column 16, line 30), this species is embraced by both sets of claims. Claim 11 of the instant application is equivalent to claim 7 of the '860 patent because both claims are for compositions suitable for controlling fungi, comprising a solid or liquid carrier and a compound of formula I. Thus, instant claims 1-2, 5, and 11 have a problem of obvious-type double patenting with the '860 claims 1-4 and 7. Claims 13-16 are rendered obvious because the claimed subgenera of 10/555894 can be encompassed by both sets of claims. In addition, variable Ra can be a halogen, oxo, or a C₁-C₆-alkyl group. Grote et al. are making hydrogen, an oxo, halogen, and C₁-C₆-alkyl groups equivalent to one another. This rejection is maintained because Grote et al. assert that an oxo group is equivalent to hydrogen because the ring can be substituted with any of the groups that are included as a part of variable Ra.

Conclusion

 THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37

Art Unit: 1624

CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Noble Jarrell whose telephone number is (571) 272-9077. The examiner can normally be reached on M-F 7:30 A.M - 6:00 P.M. EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. James O. Wilson can be reached on (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Noble Jarrell/ Examiner, Art Unit 1624 /James O. Wilson/ Supervisory Patent Examiner Art Unit 1624